Genmab Abbvie Partnership Faces Uncertain Future

Author

Reads 276

Man in Lab Coat Doing Research
Credit: pexels.com, Man in Lab Coat Doing Research

Genmab and Abbvie's partnership is built on a significant upfront payment of $3 billion and a $1 billion equity investment, which was announced in 2019. This deal gave Abbvie an exclusive option to license and co-develop Genmab's CD20-targeting bispecific antibody, epcoritamab.

The partnership has already shown promising results, with epcoritamab demonstrating impressive efficacy in clinical trials for non-Hodgkin lymphoma and chronic lymphocytic leukemia. However, the future of this partnership is uncertain due to the complexities of cancer treatment and the competitive landscape.

Genmab and Abbvie have a long-term agreement to co-develop and co-commercialize epcoritamab, but Abbvie's option to license the treatment is expected to expire in 2023.

Curious to learn more? Check out: Bbby Acquisition Co Llc

History of Collaboration

For nearly five years, AbbVie and Genmab have been more than just occasional partners, co-developing a successful antibody program in oncology.

The collaboration started in 2020 and wasn't a small-scale co-development deal, with AbbVie paying Genmab $750 million upfront.

The total value of the agreement potentially reaches $3.15 billion, a significant investment in their joint success.

Credit: youtube.com, Genmab and AbbVie Partnership

AbbVie and Genmab agreed to co-commercialize epcoritamab in the U.S. and Japan, while AbbVie would handle commercialization in the rest of the world.

The partnership was seen as a high-profile pairing, with a dynamic European innovator teaming up with a big U.S. pharma looking to expand its cancer pipeline.

Genmab's CEO, Jan van de Winkel, called the alliance a "transformative collaboration" that would allow Genmab to "accelerate, broaden, and maximize the development of some of its promising early-stage bispecific antibodies."

In March 2025, AbbVie initiated a lawsuit against Genmab, alleging the misappropriation of trade secrets related to ADC technology.

AbbVie claims the use of disaccharides to enhance the hydrophilicity of drug-linkers in ADCs is proprietary technology.

The lawsuit centers on Genmab's acquisition of ProfoundBio, which developed the ADC rinatabart sesutecan (Rina-S).

Rina-S is currently in phase 3 for ovarian cancer and other solid tumors.

Genmab acquired ProfoundBio in May 2024, just a few months before AbbVie filed the lawsuit.

$3.9B U.S. Development Agreement

A diverse group of professionals engaged in teamwork and collaboration within a modern office setting.
Credit: pexels.com, A diverse group of professionals engaged in teamwork and collaboration within a modern office setting.

Genmab and AbbVie have entered into a significant development agreement worth $3.9 billion. This agreement is a major milestone in the partnership between the two companies.

The deal includes a $2.5 billion upfront payment from AbbVie to Genmab, which is a substantial sum that will likely be used to further develop Genmab's portfolio of immunology and cancer treatments.

Genmab's existing portfolio includes several promising programs, including epcoritamab and tafasitamab, which are both being developed in collaboration with AbbVie.

Check this out: Standstill Agreement

Risks and Uncertainty

The lawsuit between AbbVie and Genmab has added undeniable strain to their partnership. This is unusual because litigation usually follows a breakdown, not sparks one.

In most cases, a lawsuit would come after a contract has been terminated, but here it's unfolding while the multi-billion-dollar oncology alliance is still very much alive. This is a different scenario than the dispute between Johnson & Johnson and ChemImage, which arose only after J&J terminated their contract.

Scientists in lab coats work with test tubes in a modern laboratory.
Credit: pexels.com, Scientists in lab coats work with test tubes in a modern laboratory.

The stakes are high, with Genmab defending its potential blockbuster ADC, Rina-S, in phase 3, while AbbVie has equally strong reasons to keep epcoritamab on track. This puts the companies' interests directly against one another, with Rina-S potentially competing with AbbVie's Elahere in ovarian cancer.

It's not just about the lawsuit itself, but also how it will impact the collaboration's dynamics. The outcome will be crucial in determining the future of their partnership.

Frequently Asked Questions

Did AbbVie buy Genmab?

AbbVie and Genmab formed a partnership, not a purchase, with AbbVie paying $750 million upfront and potentially up to $3.15 billion in total. They will co-commercialize epcoritamab in the US and Japan, with AbbVie handling commercialization elsewhere.

Antoinette Cassin

Senior Copy Editor

Antoinette Cassin is a seasoned copy editor with over a decade of experience in the field. Her expertise lies in medical and insurance-related content, particularly focusing on complex areas such as medical malpractice and liability insurance. Antoinette ensures that every piece of writing is clear, accurate, and free of legal and grammatical errors.

Love What You Read? Stay Updated!

Join our community for insights, tips, and more.